C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis

Jennifer K. Mulligan, Kunal Patel, Tucker Williamson, Nicholas Reaves, William Wise Crosby Carroll, Sarah E. Stephenson, Peng Gao, Richard R. Drake, Benjamin A. Neely, Stephen Tomlinson, Rodney J. Schlosser, Carl Atkinson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease with an unknown etiology. Recent studies have implicated the complement system as a potential modulator of disease immunopathology. We performed proteomic pathway enrichment analysis of differentially increased proteins, and found an enrichment of complement cascade pathways in the nasal mucus of individuals with CRSwNP as compared to control subjects. Sinonasal mucus levels of complement 3 (C3) correlated with worse subjective disease severity, whereas no significant difference in systemic C3 levels could be determined in plasma samples. Given that human sinonasal epithelial cells were the predominate sinonasal source of C3 and complement anaphylatoxin 3a (C3a) staining, we focused on their role in in vitro studies. Baseline intracellular C3 levels were higher in CRSwNP cells, and following exposure to Aspergillus fumigatus (Af) extract, they released significantly more C3 and C3a. Inhibition of complement 3a receptor (C3aR) signaling led to a decrease in Af-induced C3 and C3a release, both in vitro and in vivo. Finally, we found in vivo that C3aR deficiency or inhibition significantly reduced inflammation and CRS development in a mouse model of Af-induced CRS. These findings demonstrate that local sinonasal complement activation correlates with subjective disease severity, and that local C3aR antagonism significantly ameliorates Af-induced CRS in a rodent model.

Original languageEnglish (US)
Pages (from-to)1375-1385
Number of pages11
JournalMucosal Immunology
Volume11
Issue number5
DOIs
StatePublished - Sep 1 2018

Fingerprint

Complement C3a
Anaphylatoxins
Complement C3
Aspergillus fumigatus
Nasal Polyps
Complement Receptors
Mucus
Therapeutics
Complement Activation
Nose
Proteomics
Rodentia
Epithelial Cells
Staining and Labeling
Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Mulligan, J. K., Patel, K., Williamson, T., Reaves, N., Carroll, W. W. C., Stephenson, S. E., ... Atkinson, C. (2018). C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. Mucosal Immunology, 11(5), 1375-1385. https://doi.org/10.1038/s41385-018-0048-x

C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. / Mulligan, Jennifer K.; Patel, Kunal; Williamson, Tucker; Reaves, Nicholas; Carroll, William Wise Crosby; Stephenson, Sarah E.; Gao, Peng; Drake, Richard R.; Neely, Benjamin A.; Tomlinson, Stephen; Schlosser, Rodney J.; Atkinson, Carl.

In: Mucosal Immunology, Vol. 11, No. 5, 01.09.2018, p. 1375-1385.

Research output: Contribution to journalArticle

Mulligan, JK, Patel, K, Williamson, T, Reaves, N, Carroll, WWC, Stephenson, SE, Gao, P, Drake, RR, Neely, BA, Tomlinson, S, Schlosser, RJ & Atkinson, C 2018, 'C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis', Mucosal Immunology, vol. 11, no. 5, pp. 1375-1385. https://doi.org/10.1038/s41385-018-0048-x
Mulligan, Jennifer K. ; Patel, Kunal ; Williamson, Tucker ; Reaves, Nicholas ; Carroll, William Wise Crosby ; Stephenson, Sarah E. ; Gao, Peng ; Drake, Richard R. ; Neely, Benjamin A. ; Tomlinson, Stephen ; Schlosser, Rodney J. ; Atkinson, Carl. / C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. In: Mucosal Immunology. 2018 ; Vol. 11, No. 5. pp. 1375-1385.
@article{d0478584a9f24621bd48168d67e4381b,
title = "C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis",
abstract = "Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease with an unknown etiology. Recent studies have implicated the complement system as a potential modulator of disease immunopathology. We performed proteomic pathway enrichment analysis of differentially increased proteins, and found an enrichment of complement cascade pathways in the nasal mucus of individuals with CRSwNP as compared to control subjects. Sinonasal mucus levels of complement 3 (C3) correlated with worse subjective disease severity, whereas no significant difference in systemic C3 levels could be determined in plasma samples. Given that human sinonasal epithelial cells were the predominate sinonasal source of C3 and complement anaphylatoxin 3a (C3a) staining, we focused on their role in in vitro studies. Baseline intracellular C3 levels were higher in CRSwNP cells, and following exposure to Aspergillus fumigatus (Af) extract, they released significantly more C3 and C3a. Inhibition of complement 3a receptor (C3aR) signaling led to a decrease in Af-induced C3 and C3a release, both in vitro and in vivo. Finally, we found in vivo that C3aR deficiency or inhibition significantly reduced inflammation and CRS development in a mouse model of Af-induced CRS. These findings demonstrate that local sinonasal complement activation correlates with subjective disease severity, and that local C3aR antagonism significantly ameliorates Af-induced CRS in a rodent model.",
author = "Mulligan, {Jennifer K.} and Kunal Patel and Tucker Williamson and Nicholas Reaves and Carroll, {William Wise Crosby} and Stephenson, {Sarah E.} and Peng Gao and Drake, {Richard R.} and Neely, {Benjamin A.} and Stephen Tomlinson and Schlosser, {Rodney J.} and Carl Atkinson",
year = "2018",
month = "9",
day = "1",
doi = "10.1038/s41385-018-0048-x",
language = "English (US)",
volume = "11",
pages = "1375--1385",
journal = "Mucosal Immunology",
issn = "1933-0219",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis

AU - Mulligan, Jennifer K.

AU - Patel, Kunal

AU - Williamson, Tucker

AU - Reaves, Nicholas

AU - Carroll, William Wise Crosby

AU - Stephenson, Sarah E.

AU - Gao, Peng

AU - Drake, Richard R.

AU - Neely, Benjamin A.

AU - Tomlinson, Stephen

AU - Schlosser, Rodney J.

AU - Atkinson, Carl

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease with an unknown etiology. Recent studies have implicated the complement system as a potential modulator of disease immunopathology. We performed proteomic pathway enrichment analysis of differentially increased proteins, and found an enrichment of complement cascade pathways in the nasal mucus of individuals with CRSwNP as compared to control subjects. Sinonasal mucus levels of complement 3 (C3) correlated with worse subjective disease severity, whereas no significant difference in systemic C3 levels could be determined in plasma samples. Given that human sinonasal epithelial cells were the predominate sinonasal source of C3 and complement anaphylatoxin 3a (C3a) staining, we focused on their role in in vitro studies. Baseline intracellular C3 levels were higher in CRSwNP cells, and following exposure to Aspergillus fumigatus (Af) extract, they released significantly more C3 and C3a. Inhibition of complement 3a receptor (C3aR) signaling led to a decrease in Af-induced C3 and C3a release, both in vitro and in vivo. Finally, we found in vivo that C3aR deficiency or inhibition significantly reduced inflammation and CRS development in a mouse model of Af-induced CRS. These findings demonstrate that local sinonasal complement activation correlates with subjective disease severity, and that local C3aR antagonism significantly ameliorates Af-induced CRS in a rodent model.

AB - Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease with an unknown etiology. Recent studies have implicated the complement system as a potential modulator of disease immunopathology. We performed proteomic pathway enrichment analysis of differentially increased proteins, and found an enrichment of complement cascade pathways in the nasal mucus of individuals with CRSwNP as compared to control subjects. Sinonasal mucus levels of complement 3 (C3) correlated with worse subjective disease severity, whereas no significant difference in systemic C3 levels could be determined in plasma samples. Given that human sinonasal epithelial cells were the predominate sinonasal source of C3 and complement anaphylatoxin 3a (C3a) staining, we focused on their role in in vitro studies. Baseline intracellular C3 levels were higher in CRSwNP cells, and following exposure to Aspergillus fumigatus (Af) extract, they released significantly more C3 and C3a. Inhibition of complement 3a receptor (C3aR) signaling led to a decrease in Af-induced C3 and C3a release, both in vitro and in vivo. Finally, we found in vivo that C3aR deficiency or inhibition significantly reduced inflammation and CRS development in a mouse model of Af-induced CRS. These findings demonstrate that local sinonasal complement activation correlates with subjective disease severity, and that local C3aR antagonism significantly ameliorates Af-induced CRS in a rodent model.

UR - http://www.scopus.com/inward/record.url?scp=85048595370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048595370&partnerID=8YFLogxK

U2 - 10.1038/s41385-018-0048-x

DO - 10.1038/s41385-018-0048-x

M3 - Article

C2 - 29907871

AN - SCOPUS:85048595370

VL - 11

SP - 1375

EP - 1385

JO - Mucosal Immunology

JF - Mucosal Immunology

SN - 1933-0219

IS - 5

ER -